Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Posted: Monday, June 24, 2019

Suresh S. Ramalingam, MD, of Emory University, discusses the value of negative research findings in light of the ECOG-ACRIN 5508 trial, which showed that the combination of pemetrexed and bevacizumab did not offer a survival benefit vs single agents in advanced nonsquamous NSCLC.